|
1
|
American Cancer Society, . Cancer Facts
& Figures 2015. American Cancer Society; Atlanta, GA: 2015
|
|
2
|
Wei KR, Chen WQ, Zhang SW, Zheng RS, Wang
YN and Liang ZH: Epidemiology of uterine corpus cancer in some
cancer registering areas of China from 2003–2007. Zhonghua Fu Chan
Ke Za Zhi. 47:445–451. 2012.(In Chinese). PubMed/NCBI
|
|
3
|
Schouten LJ, Goldbohm RA and van den
Brandt PA: Anthropometry, physical activity, and endometrial cancer
risk: Results from the Netherlands cohort study. Int J Gynecol
Cancer. 16 Suppl 2:S4922006. View Article : Google Scholar
|
|
4
|
Thigpen JT, Brady MF, Homesley HD,
Malfetano J, DuBeshter B, Burger RA and Liao S: Phase III trial of
doxorubicin with or without cisplatin in advanced endometrial
carcinoma: A gynecologic oncology group study. J Clin Oncol.
22:3902–3908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eggleton P, Bremer E, Dudek E and Michalak
M: Calreticulin, a therapeutic target? Expert Opin Ther Targets.
20:1137–1147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Panaretakis T, Kepp O, Brockmeier U,
Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N,
Pierron G, van Endert P, et al: Mechanisms of pre-apoptotic
calreticulin exposure in immunogenic cell death. EMBO J.
28:578–590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garg AD, Krysko DV, Verfaillie T,
Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu
C, Roebroek AJ, et al: A novel pathway combining calreticulin
exposure and ATP secretion in immunogenic cancer cell death. EMBO
J. 31:1062–1079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fucikova J, Becht E, Iribarren K, Goc J,
Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, et al:
Calreticulin expression in human non-small cell lung cancers
correlates with increased accumulation of antitumor immune cells
and favorable prognosis. Cancer Res. 76:1746–1756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du XL, Hu H, Lin DC, Xia SH, Shen XM,
Zhang Y, Luo ML, Feng YB, Cai Y, Xu X, et al: Proteomic profiling
of proteins dysregulated in Chinese esophageal squamous cell
carcinoma. J Mol Med (Berl). 85:863–875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaksman O, Davidson B, Tropé C and Reich
R: Calreticulin expression is reduced in high-grade ovarian serous
carcinoma effusions compared with primary tumors and solid
metastases. Hum Pathol. 44:2677–2683. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gebremeskel S and Johnston B: Concepts and
mechanisms underlying chemotherapy induced immunogenic cell death:
Impact on clinical studies and considerations for combined
therapies. Oncotarget. 6:41600–41619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang T, Srivastava S, Hartman M, Buhari
SA, Chan CW, Iau P, Khin LW, Wong A, Tan SH, Goh BC and Lee SC:
High expression of intratumoral stromal proteins is associated with
chemotherapy resistance in breast cancer. Oncotarget.
7:55155–55168. 2016.PubMed/NCBI
|
|
13
|
Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen
CN, Lai DM, Hsieh LJ, Wang BT, Tsao PN, Lee H, et al: Calreticulin
expression in neuroblastoma-a novel independent prognostic factor.
Ann Oncol. 16:314–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kageyama S, Isono T, Matsuda S, Ushio Y,
Satomura S, Terai A, Arai Y, Kawakita M, Okada Y and Yoshiki T:
Urinary calreticulin in the diagnosis of bladder urothelial
carcinoma. Int J Urol. 16:481–486. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM,
Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H and Chang KJ: Identification
of calreticulin as a prognosis marker and angiogenic regulator in
human gastric cancer. Ann Surg Oncol. 16:524–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Erić A, Juranić Z, Milovanović Z, Marković
I, Inić M, Stanojević-Bakić N and Vojinović-Golubović V: Effects of
humoral immunity and calreticulin overexpression on postoperative
course in breast cancer. Pathol Oncol Res. 15:89–90. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wemeau M, Kepp O, Tesnière A, Panaretakis
T, Flament C, De Botton S, Zitvogel L, Kroemer G and Chaput N:
Calreticulin exposure on malignant blasts predicts a cellular
anticancer immune response in patients with acute myeloid leukemia.
Cell Death Dis. 1:e1042010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng RQ, Chen YB, Ding Y, Zhang R, Zhang
X, Yu XJ, Zhou ZW, Zeng YX and Zhang XS: Expression of calreticulin
is associated with infiltration of T-cells in stage IIIB colon
cancer. World J Gastroenterol. 16:2428–2434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lwin ZM, Guo C, Salim A, Yip GW, Chew FT,
Nan J, Thike AA, Tan PH and Bay BH: Clinicopathological
significance of calreticulin in breast invasive ductal carcinoma.
Mod Pathol. 23:1559–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gardai SJ, McPhillips KA, Frasch SC,
Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg
PA, Michalak M and Henson PM: Cell-surface calreticulin initiates
clearance of viable or apoptotic cells through trans-activation of
LRP on the phagocyte. Cell. 123:321–334. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tongu M, Harashima N, Yamada T, Harada T
and Harada M: Immunogenic chemotherapy with cyclophosphamide and
doxorubicin against established murine carcinoma. Cancer Immunol
Immunother. 59:769–777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perez CA, Fu A, Onishko H, Hallahan DE and
Geng L: Radiation induces an antitumour immune response to mouse
melanoma. Int J Radiat Biol. 85:1126–1136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Obeid M, Panaretakis T, Joza N, Tufi R,
Tesniere A, van Endert P, Zitvogel L and Kroemer G: Calreticulin
exposure is required for the immunogenicity of gamma-irradiation
and UVC light-induced apoptosis. Cell Death Differ. 14:1848–1850.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bifulco G, Miele C, Di Jeso B, Beguinot F,
Nappi C, Di Carlo C, Capuozzo S, Terrazzano G, Insabato L and
Ulianich L: Endoplasmic reticulum stress is activated in
endometrial adenocarcinoma. Gynecol Oncol. 125:220–225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leslie KK, Sill MW, Fischer E, Darcy KM,
Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, et
al: A phase II evaluation of gefitinib in the treatment of
persistent or recurrent endometrial cancer: A gynecologic oncology
group study. Gynecol Oncol. 129:486–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang H, Liu Z, Gou Y, Qin Y, Xu Y, Liu J
and Wu JZ: Apoptosis and necrosis induced by novel realgar quantum
dots in human endometrial cancer cells via endoplasmic reticulum
stress signaling pathway. Int J Nanomedicine. 10:5505–5512. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Boo S, Kopecka J, Brusa D, Gazzano E,
Matera L, Ghigo D, Bosia A and Riganti C: iNOS activity is
necessary for the cytotoxic and immunogenic effects of doxorubicin
in human colon cancer cells. Mol Cancer. 8:1082009. View Article : Google Scholar : PubMed/NCBI
|
